Login
Navigate Fool.com
Will EBS beat
the market?
Community Rating: 4 Stars: Favorite

26.71 -0.07 (-0.26%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $26.70
Previous Close $26.78
Daily Range $26.24 - $27.17
52-Week Range $13.88 - $28.48
Market Cap $982.2M
P/E Ratio 31.51
Dividend (Yield) $0.00 (0.0%)
Volume 210,134
Average Daily Volume 438,927
Current FY EPS $1.19

How do you think EBS
will perform against the market?

Top EBS Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted July 30, 2011

The stock has bounced upward from these levels twice already this year. The company claims that a dramatic drop in Biothrax revenues last quarter was due to an &quot;internal process of redeployment&q … More

0 Replies Reply Report this Post
 

fewl10 (< 20)
Submitted December 15, 2008

Good grief. What a bubble

0 Replies Reply Report this Post

News & Commentary

You Shouldn't Ignore Gilead's Idelalisib

Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.

Emergent BioSolutions to Webcast Presentation at Credit Suisse 2013 Healthcare Conference

Emergent BioSolutions to Release Third Quarter 2013 Financial Results and Conduct a Conference Call

Investing in Counteracting Biological and Chemical Agents

Biological and chemical agents are a lethal scourge of war, but Emergent Biosciences is developing countermeasures to a wide range of such agents.

Sector Update: Healthcare Shares Higher; eHealth Signs Agreement to Enroll Individuals

Sector Update: Healthcare

Emergent BioSolutions Appoints Barry Labinger as Executive Vice President of the Company and Preside

Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2013

Emergent BioSolutions Closes on Its Acquisition of Healthcare Protective Products Division from Brac

Emergent BioSolutions to Webcast Presentation at Wedbush 2013 Life Sciences Management Access Confer

See More EBS News...

Sector

Healthcare

Industry

Drugs

Emergent BioSolutions (EBS) Description

Emergent BioSolutions makes the only FDA-approved anthrax vaccine. Website: http://www.emergentbiosolutions.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks